You are here

Structural & Congenital Heart Disease


Next-day discharge after minimalist transcatheter aortic valve replacement (TAVR) was safe for patients who didn’t experience perioperative complications and was linked to better one-year outcomes versus patients discharged later, according to a single-center study published in JACC: Cardiovascular Interventions.

The American Heart Association (AHA) and American College of Cardiology (ACC) rolled out new guidelines for managing valvular heart disease (VHD) in 2017, marking the second overhaul of VHD recommendations in three years—a move attributable to “extensive new data” that have shaped the way clinicians treat valve disease.

A larger valve option and more appropriate valve sizing using preprocedural imaging may eliminate the previously reported survival disparity between men and women undergoing transcatheter aortic valve replacement (TAVR), a new study in JACC: Cardiovascular Interventions suggests.

Procedures to replace or repair patients’ tricuspid valves (TVs) remain rare but have increased in recent years, according to a study in the Journal of the American College of Cardiology. But despite this increased volume, in-hospital mortality has remained steady at 8.8 percent.

The Centera transcatheter heart valve (THV) shows promise in addressing the “Achilles’ heel” of transcatheter aortic valve replacement (TAVR), according to Luis Nombela-Franco, MD, PhD, who wrote an editorial about the device’s pivotal study published in the Journal of the American College of Cardiology.


Recent Headlines

National accreditation program aims to benefit adults with congenital heart disease

To better serve the 1.4 million U.S. adults living with congenital heart disease, the Adult Congenital Heart Association (ACHA) on Sept. 14 announced the start of a national accreditation program.

Mobile health device usage leads to fewer deaths, hospitalizations

Living in a technological era could mean quicker, more accurate and even smartphone-linked medical diagnoses, one study of mobile health device use in India has suggested.

NEJM research: PFO closure reduces risk of recurrent stroke

The New England Journal of Medicine tackled patent foramen ovale (PFO) closure in its Sept. 13 issue, with three separate studies and an editorial devoted to the topic. 

Transcatheter closure may be alternative solution of aortic anastomosis leak

An aortic anastomosis leak (AAL) is a complication that’s difficult to address after surgery, but a case study from Chinese researchers offers a possible alternative to the usual method of handling this challenging issue—which is to operate.

BAV boasts 70% success rate in patients with congenital aortic stenosis

Balloon aortic valvuloplasty (BAV), the most common treatment for isolated congenital aortic stenosis (AS), demonstrated a 70 percent success rate in a study of more than 1,000 patients.

Prevention takes on new meaning with embryos, and predicting frailty in the elderly

U.S. scientists in July edited the DNA of a human embryo. It’s a first, it’s just the beginning and could someday mean the end of children born with hypertrophic cardiomyopathy. Imagine wiping out sudden cardiac death in young athletes someday.  

MR reduction after TMVR with the FORTIS valve maintained at 2 years

The first report to address long-term outcomes for patients with severe native mitral regurgitation (MR) who are treated with transcatheter mitral valve replacement has found that post-procedural reductions in MR held up over time, with no significant recurrence upon two-year follow-up.

Researchers: Off-label TAVRs yield ‘acceptable results’

Patients receiving off-label transcatheter aortic valve replacement (TAVR) are more likely to suffer adverse outcomes than other TAVR patients, according to new research. However, risk-adjusted mortality is similar between the two groups at one year post-procedure.

TAVR, SAVR produce similar long-term health gains

For patients with severe aortic stenosis (AS) at intermediate surgical risk, transcatheter aortic valve replacement (TAVR)—especially the transfemoral approach—might be a good solution.

TAVI utilization rate highest Northeast US; mortality highest in South

Transcatheter aortic valve implantation (TAVI) has skyrocketed in the United States, jumping from 24.8 implants per million adults in 2012 to 63.2 in 2014. A recent study examined regional differences in mortality, utilization and healthcare resource use.